3- Wednesday Research News – 28th April

1 – Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization

• There is an urgent need for treatments to prevent the progression to severe COVID-19 and hospitalization.
• This is a double-blind randomized multicenter study in 36 centers in the U.S. and Puerto Rico investigating the potential of a five-day treatment with nitazoxanide 300 mg extended release tablets in 379 outpatients with mild or moderate laboratory-confirmed COVID-19 with an onset of symptoms no more than 72 hours before inclusion.
• Treatment of mild or moderate COVID-19 with a five-day course of oral nitazoxanide was safe and well tolerated and was associated with an 85% reduction in the progression to severe illness.

Source: MedRxiv

Date: April 2021

2- Post-COVID seizure: A new feature of “long-COVID”

• Novel coronavirus SARS-CoV-2 has created unprecedented healthcare challenges. Neurologic deficits are often an important presenting symptom.
• To date, the only reported post-infectious COVID-19 manifestations of neurologic disease include cognitive deficits and dysfunction of the peripheral nervous system.
• This study reports that seizure can also be a post-COVID-19 or “long-COVID” complication.

Source: ScienceDirect

3- Prevalence and Predictors of in-Hospital Mortality of Patients Hospitalized with COVID-19 Infection

• The severity and mortality from COVID-19 infection vary among populations.
• The aim of this study was to determine the prevalence and predictors of mortality among patients hospitalized with COVID-19 infection in a tertiary care hospital in Oman.
• In this cohort, mortality in hospitalized COVID-19 patients was high and was associated with advanced age, heart diseases, liver disease, high ferritin, ARDS, sepsis and ICU admission.
• These high-risk groups should be prioritized for COVID-19 vaccinations.

Source: ScienceDirect

4- Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers

• Concerns are prevailing about the safety and side effects from BNT162b2 mRNA COVID-19 vaccine.
• A randomized, cross-sectional study was performed to investigate the side effects of BNT162b2 vaccine using an independent online questionnaire gathering responses from healthcare workers (HCWs) with detailed review of organ systems.
• The commonly reported symptoms (occurrence in the descending order) include soreness, fatigue, myalgia, headache, chills, fever, joint pain, nausea, muscle spasm, sweating, dizziness, flushing, feelings of relief, brain fogging, anorexia, localized swelling, decreased sleep quality, itching, tingling, diarrhea, nasal stuffiness, and palpitations.

Source: ScienceDirect

5- Oral Antiseptic against Coronavirus: In Vitro and Clinical Evidence

• Angiotensin converting enzyme II (ACE2) is the cellular receptor for SARS-CoV-2, so ACE2-expressing cells can act as target cells and are susceptible to infection.
• ACE2 receptors are highly expressed in the oral cavity so this may be a potential high-risk route for SARS-CoV-2 infection.
• This study aims to evaluate the available evidence testing the in vitro and in vivo effects of oral antiseptics to inactivate or eradicate coronaviruses.
• There is sufficient in vitro evidence to support the use of antiseptics to potentially reduce the viral load of SARS-CoV-2 and other coronaviruses.
• However, in vivo evidence for most oral antiseptics is limited.
• Randomized clinical trials with a control group are needed to demonstrate its clinical efficacy

Source: ScienceDirect

6- Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2

• The clinical manifestations of COVID-19 are highly variable ranging from mild presentations to severe.
• This led the scientists to search for ways to monitor disease progression or to predict outcomes in COVID-19.
• The kinetics and breadth of immune responses during COVID-19 appear to follow a trend which is consistent to the predominant pathological alterations.
• This study presents present details about the current status of the evaluation. Understanding of the COVID-19 related alterations of the innate and adaptive immune responses may help to promote the vaccine development and immunological interventions.

Source: ScienceDirect

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Clinical Research E-News ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Clinical Research FNN E-News, for a publication of News

Read & Download FNN Issue 8 of April 2020 FNN News